Moreover, there is evidence that PKCε could be a therapeutic target, as its suppression may improve cardiovascular alterations due to chronic hypobaric hypoxia and the development of pulmonary hypertension [22]. This evidence concerns the gene PRKCE and pulmonary hypertension.